• Toolbar regrouped into detection, edit mode (Select / Add / Delete with shortcut hints) and history, with grid, crop, templates and spot meanings on a second row
• A four-step workflow bar and a status line above the image explain the current mode; rotation, zoom, contrast and history now sit in a collapsible panel so the image appears higher on the page
• Clicking a results row highlights it, and the signal column shows a bar relative to the strongest spot; keyboard shortcuts V, A, D, C, Esc and Cmd/Ctrl+Z are supported
• Undo after dragging an ROI now returns it to where it was, and the page no longer scrolls sideways on narrow screens

• New Western blot densitometry tool — frame all lanes with one box, and lanes are counted, split at the faintest columns and centred on their signal
• One horizontal drag marks the band in every lane at once; the second row defaults to the loading control, and Snap bands corrects smiling gels lane by lane
• Lane-baseline, border-median or no background correction; loading-control normalisation and fold change vs a chosen control group
• Bar chart builds itself from lane groups with mean ± SD or SEM, individual points and Holm-adjusted Welch tests vs control, exportable as PNG/SVG alongside CSV

• Analysis mode keeps the plot in front. Choose a gate tool and drag on the plot to make the first gate; axis details and export open when you need them, while session restore stays visible.
• Add up to four plots and assign a sample by dragging it from the file list or choosing it above the plot. A gate drawn on that plot belongs to that sample.
• Selecting a sample no longer hides it. Show and hide are separate controls.
• Skipping compensation is labeled on that sample, so an uncompensated file does not look unchanged. Files uploaded together stay in the order you selected.

A Nature Cardiovascular Research mouse and cell study finds that aging thins cardiac lymphatics and tightens their junctions, making immune cells and waste harder to clear. Nuclear IL-33 and falling VEGFC are the mechanistic clues. Restoring VEGFC rebuilt vessel density and cut macrophages, but did not fix diastolic function. This is not proof of a human therapy.

Human SFEMG and rodent work in JCI 2026 show sarcopenic weakness can come from postsynaptic NaV1.4 loss at the NMJ, not just wasting. Partial ClC-1 inhibition restored transmission-related force in aged rats; this is not a human drug claim.